Search
Outlook Therapeutics Inc
OTLKAdd to Watchlist
0.641USD
-0.025-3.75%
Close 09-08 16:00（ET）
119.93MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-09-04The current earnings forecast score of Outlook Therapeutics Inc is 7.00, ranking 299 out of 368 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 21.00 and a low of 1.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
4.900
Target Price
+635.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Outlook Therapeutics Inc
OTLK
4
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Outlook Therapeutics Inc's expected revenue for the next quarter?
Outlook Therapeutics Inc's expected revenue is 15.08M.
What is Outlook Therapeutics Inc's price target?
Analysts forecast that Outlook Therapeutics Inc's price target is USD 8.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 1.00.
How have Outlook Therapeutics IncOTLK's recent earnings per share performed?
The market expectation was USD -0.15, while Outlook Therapeutics IncOTLK's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD -0.07.
What is the analyst rating for Outlook Therapeutics Inc?
Based on the ratings of Outlook Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.